<DOC>
	<DOCNO>NCT00101816</DOCNO>
	<brief_summary>The purpose study see effect investigational drug ( BMS-354825 ) subject currently myeloid blast phase chronic myeloid leukemia ( CML ) either resistant intolerant imatinib mesylate . Another purpose study see side effect drug may subject .</brief_summary>
	<brief_title>Dasatinib ( BMS-354825 ) Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant Intolerant Imatinib Mesylate</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Subjects myeloid blast phase chronic myeloid leukemia Subjects either resistant intolerant imatinib mesylate Subjects eligible willing undergo transplantation Serious uncontrolled medical disorder active infection Uncontrolled significant heart problem , congestive heart failure , recent heart attack , etc Subjects receive medication may affect heart rhythm Other malignancy/cancer CML History significant bleeding disorder unrelated CML Pregnant breastfeed woman ( subject must avoid become pregnant ) Subjects receive imatinib within 7 day , interferon cytarabine within 14 day , targeted anticancer medication within 14 day , antineoplastic agent ( hydroxyurea anagrelide ) within 28 day , investigation medication 28 day Subject receive medication affect platelet function anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Myeloid blast phase Chronic Myeloid Leukemia ( CML )</keyword>
</DOC>